BI-1347
BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM) . BI-1347 shows anti-tumoral activity[1][2].
Product Specifications
CAS Number
2163056-91-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bi-1347.html
Purity
99.84
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(N(C)C)CN1N=CC(C2=CC=C(C3=CN=CC4=C3C=CC=C4)C=C2)=C1
Molecular Formula
C22H20N4O
Molecular Weight
356.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Harald Engelhardt, et al. New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors.|[2]Hofmann MH, et al. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance. Mol Cancer Ther. 2020 Apr;19 (4) :1018-1030.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK8
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC400683 20 µg
P cadherin (CDH3) (NM_001793) Human Over-expression Lysate
Sign In for Pricing
View Details 
